Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 85 от 222

Recruiting Phase 2

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Systemic Lupus Erythematosus Active Refractory Rheumatoid Arthritis

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).

Начало: 16.07.2025 Край: 09.03.2029 Възраст: 18–75 г. Treatment

Australia, Belgium, France +6 Amgen NCT06570798

Recruiting Phase 1

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma in Relapse Myeloma Multiple Multiple Myeloma Progression Neoplasms by Histologic Type +10

The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.

Начало: 16.07.2025 Край: 01.05.2042 Възраст: от 18 г. Treatment

Australia, United States Kelonia Therapeutics, Inc. NCT07075185

Recruiting Phase 2

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria

Phenylketonuria (PKU)

The goal of this Phase 2, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of oral JNT-517 in adolescents (12 to less than 18 years of age) with PKU. Participants will receive either JNT-517 or placebo and will be blinded to their treatment assignment. Participants will have a 4 in 5 (or 80%) chance of receiving JNT-517. The study will last for up to 63 days including a Screening period, Treatment period and Follow-up period for safety. Participants will: * Take 75 mg JNT-517 or a placebo BID (2x per day) for 28 days * Visit the clinic or have a mobile health nurse visit your home for checkups and tests * Collect urine sample at home and bring to clinic on specified days * Keep a food diary 3 days before each study visit

Начало: 16.07.2025 Край: 09.05.2026 Възраст: 12–17 г.

Australia, United States Otsuka Pharmaceutical Development & Commercialization, NCT06637514

Recruiting Phase 3

A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Kidney Disease

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo. Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed in 1 of the 2 treatment groups by chance (either mezagitamab or placebo) at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. The participants will receive either mezagitamab or placebo for almost half a year in two 1-year cycles. They will be observed for another half year in each 1-year cycle and will have check-ups about every month during this time. In the open-label group, a small number of participants who have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab. During the study, participants will visit their study clinic several times.

Начало: 15.07.2025 Край: 14.01.2030 Възраст: от 18 г. Treatment

Argentina, Australia, Austria +23 Takeda NCT06963827

Recruiting Phase 2

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis (AD)

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Начало: 15.07.2025 Край: 31.03.2027 Възраст: 18–75 г.

Canada, United States Bluefin Biomedicine, Inc. NCT07105488

Recruiting Phase 1/2

CAR-T Immunotherapy Targeting CD19- ALL

B-cell Leukemia

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Начало: 15.07.2025 Край: 15.12.2029 Възраст: 6–75 г.

China Shenzhen Geno-Immune Medical Institute NCT04016129

Recruiting Phase 1/2

Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes

Myelodysplastic Syndromes

The goal of this interventional clinical trial is to evaluate the safety and tolerability of leflunomide in combination with decitabine as treatment for patients with relapsed or refractory myelodysplastic syndromes (R/R MDS). The main question this study aims to answer are to evaluate and estimate the maximum tolerated doses and/or biologically active doses of the combination of leflunomide-decitabine in participants. Decitabine will be administered at a dose of 20 mg/m2 by continuous intravenous infusion over one hour repeated daily for 5 days with repeating cycle every 4 weeks. Leflunomide is administered orally at 10 to 20 mg once daily (without a loading dose) for 14 to 21 days, as part of a 28-day treatment cycle in adult subjects with R/R MDS. After 12 cycles (study duration) responding patients can continue progression with the assigned doses.

Начало: 15.07.2025 Край: 01.10.2028 Възраст: от 18 г.

United States West Virginia University NCT06923488

Recruiting

Evaluation of Tenting the Schneiderian Membrane of the Maxillary Sinus Using Titanium Mesh.

Maxillary Sinus Floor Augmentation

Twenty posterior maxillary edentulous sites requiring open sinus augmentation for staged dental implant placement will be studied. Group I (study group) the maxillary sinus membrane will be elevated using titanium mesh fixed by bone screws. Group II (control group) will have stainless steel screws/pins placed bucco-palatally to maintain the elevated membrane and stabilize the formed blood clot. Platelet rich fibrin (PRF) will be placed at the site of elevated membrane in both groups.

Начало: 15.07.2025 Край: 01.12.2026 Възраст: 18–60 г.

Egypt Suez Canal University NCT07035236

Recruiting Phase 1/2

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Acute Myeloid Leukemia

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML). Another goal of the study is to learn more about the function of the multi-CAR T cells and their persistency in the patients.

Начало: 15.07.2025 Край: 31.12.2028 Възраст: 2–75 г.

China Shenzhen Geno-Immune Medical Institute NCT03222674

Recruiting Phase 2

A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

Chronic Hepatitis B Infection

This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.

Начало: 15.07.2025 Край: 01.08.2028 Възраст: 18–65 г. Treatment

Bulgaria, Canada, China +11 Aligos Therapeutics NCT06963710

Recruiting

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

COPD Emphysema

The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study subjects will be followed for 3 years. The main questions it aims to answer are: Is it safe? Does it work?

Начало: 15.07.2025 Край: 31.12.2029 Възраст: 40–84 г.

Austria, Netherlands, United Kingdom +1 Apreo Health, Inc. NCT06891755

Recruiting

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Lung Cancer, Hepatocellular Carcinoma

This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.

Начало: 15.07.2025 Край: 31.12.2028 Възраст: от 18 г.

Austria, Belgium, Bulgaria +5 Hoffmann-La Roche NCT07284121

Recruiting

Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates - UK

Lung Cancer

This study involves the use of a medical device, the Creo Medical MicroBlate Flex instrument, to heat and destroy lung tumour cells using microwave energy (this is also called ablation). In this study, the investigators are investigating whether the ablation instrument can be used effectively to treat lung tumours or tumours that have spread to the lungs. If successful, using this technology may mean future patients may not need to undergo surgical removal of these types of lung tumours. The aim of this study is to evaluate the safety and performance of the MicroBlate Flex instrument in treating individuals with cancerous lung tumours that are due to be removed by surgery. All participants in the study will undergo the microwave ablation procedure, which is a separate and additional procedure to their surgical procedure. The study, funded by Creo Medical, will be conducted at sites in the UK and Italy, and will involve up to 18 participants.

Начало: 14.07.2025 Край: 01.12.2026 Възраст: от 18 г.

Italy, United Kingdom Creo Medical Limited NCT06869122

Recruiting Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

Alzheimer's Disease

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

Начало: 14.07.2025 Край: 23.02.2029 Възраст: 60–85 г. Treatment

Argentina, Australia, Brazil +14 Bristol-Myers Squibb NCT06976216

Recruiting Phase 2

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Lupus Erythematosus, Systemic Lupus Nephritis

The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.

Начало: 14.07.2025 Край: 15.06.2032 Възраст: от 16 г.

Argentina, Austria, Belgium +13 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company NCT07015983

Recruiting Early Phase 1

Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

Cutaneous Lupus Erythematosus

The goal of this study is to investigate the safety and tolerability of the topical application of SOF-SKN in healthy volunteers. The study will be divided into part 1 and part 2. Part 1, is a single ascending dose (SAD) design, while Part 2 is a multiple ascending dose (MAD) design.

Начало: 14.07.2025 Край: 01.03.2026 Възраст: 18–64 г. Treatment

Australia Noxopharm Limited NCT07072611

Recruiting

Evaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study)

Coronary Artery Disease Atherosclerosis Myocardial Ischemia

The CODEX-1 study is a multicenter retrospective observational study designed to assess the diagnostic performance of a novel software application for coronary artery disease (CAD) evaluation. The application integrates automated stenosis detection, CT-derived fractional flow reserve (CT-FFR), and plaque quantification, all performed on-site. A total of 1,000 patients who previously underwent coronary computed tomography angiography (CCTA) and diagnostic invasive coronary angiography (ICA) and/or other non-invasive imaging will be included. The study compares the diagnostic outputs of the software to current clinical practice and expert adjudication, focusing on CAD-RADS categorization, prediction of the need for percutaneous coronary intervention (PCI), and reduction in unnecessary ICA procedures.

Начало: 14.07.2025 Край: 30.04.2027 Възраст: от 18 г.

France, Netherlands, Spain Instituto de Investigación Biomédica de Salamanca NCT06977295

Recruiting

Project VIBE: Virtual Intervention for Binge Eating in Adolescents

Obesity Binge-Eating Disorder Binge Eating

The aim of this project is to pilot test a novel mobile app intervention for adolescents with dysregulated eating behaviors and elevated weight status. This intervention will incorporate evidence-informed strategies targeting self-regulation into cognitive-behavioral treatment for maladaptive eating. Adolescents will use the app for 16 weeks and provide feedback on its usability and effectiveness in managing dysregulated eating.

Начало: 14.07.2025 Край: 30.05.2027 Възраст: 13–19 г.

United States University of Pittsburgh NCT06819813

Recruiting Phase 3

Efficacy & Safety of Minoxidil SL Tablets in Men With AGA

Androgenetic Alopecia Male Pattern Baldness

This is a phase 3, multicentre, randomised, double-blinded, placebo-controlled study examining the safety and efficacy of 2.5 mg sublingual (SL) minoxidil tablets taken twice daily in the treatment of androgenetic alopecia (AGA) in men. The duration of study participation is 32 weeks including screening and safety follow up. The primary efficacy objective is to determine whether treatment with 2.5 mg SL tablets twice daily increases the number of hairs in men with AGA over 24 weeks. The primary safety objective is to evaluate the safety and tolerability of 2.5 mg SL tablets administered twice daily over 24 weeks.

Начало: 14.07.2025 Край: 01.07.2026 Възраст: от 18 г. Treatment

Australia Samson Clinical Operations Pty Ltd NCT06924632

Recruiting

HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis

Heart Defects, Congenital Anxiety in Pregnancy Depression, Postpartum Trauma, Psychological +1

Babies with single ventricle congenital heart disease (SVCHD) are often diagnosed during pregnancy. While prenatal diagnosis has important clinical benefits, it is often stressful and overwhelming for parents, and many express a need for psychological support. HeartGPS is a psychological intervention for parents who receive their baby's diagnosis of SVCHD during pregnancy. It includes 8 sessions with a psychologist, coupled with tailored educational resources, and a personalized care plan. The intervention focuses on fostering parent psychological adjustment and wellbeing, and supporting parents to bond with their baby in ways that feel right for them. Through this study, the investigators will learn if HeartGPS is useful and effective for parents and their babies when it is offered in addition to usual fetal cardiac care. The investigators will examine the effects of the HeartGPS intervention on parental anxiety, depression, and traumatic stress; fetal and infant brain development; parent-infant bonding; and infant neurobehavioral and neurodevelopmental outcomes. The investigators will also explore mechanisms associated with stress biology during pregnancy, infant brain development and neurodevelopmental outcomes, and parent and infant intervention effects.

Начало: 14.07.2025 Край: 01.12.2027 Възраст: от 18 г. Treatment

Australia, United States Children's Hospital Medical Center, Cincinnati NCT06175104

1 … 83 84 85 86 87 … 222